Described herein is a UV/HEVL-filtering SiHy contact lens that not only has a relatively high UV/HEVL filtering capability but also has an aesthetic appealing color. The bulk silicone hydrogel of the UV/HEVL-filtering SiHy contact lens comprises repeating units of (1) at least one hydrophilic vinylic monomer, (2) at least one siloxane-containing vinylic monomer and/or at least one polysiloxane vinylic crosslinker, (3) at least one UV-absorbing vinylic monomer, and (4) a least one polymerizable HEVL-absorbing compound capable of absorbing HEVL between 380 nm and 450 nm and also comprises at least one blue-tinting agent and at least one optical brightener distributed therein.
G02B 1/04 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of organic materials, e.g. plastics
B29D 11/00 - Producing optical elements, e.g. lenses or prisms
A method, instructions for which are executed from a computer-readable medium, calibrates a robotic camera system having a digital camera connected to an end-effector of a serial robot. The end-effector and camera move within a robot motion coordinate frame (“robot frame”). The method includes acquiring, using the camera, a reference image of a target object on an image plane having an optical coordinate frame, and receiving input signals, including a depth measurement and joint position signals. Separate roll and pitch offsets are determined of a target point within the reference image with respect to the robot frame while moving the robot. Offsets are also determined with respect to x, y, and z axes of the robot frame while moving the robot through another motion sequence. The offsets are stored in a transformation matrix, which is used to control the robot during subsequent operation of the camera system.
The present invention relates to Tapinarof dimethylacetamide solvate and crystalline forms thereof, processes for preparation and pharmaceutical compositions thereof. Furthermore, the invention concerns its use for the preparation of a medicament, preferably for the treatment of skin diseases.
C07C 39/21 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic part, with unsaturation outside the rings with at least one hydroxy group on a non-condensed ring
C07C 233/05 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Cav1.2 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder. ADHD, Phelan-Mc-Dermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease. Brugada Syndrome. Short QT syndrome, or early repolarization syndrome.
The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Cav1.2 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder. ADHD, Phelan-Mc-Dermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease. Brugada Syndrome. Short QT syndrome, or early repolarization syndrome.
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
The present invention relates to anti-VP1 antibodies, antibody fragments, and their uses for the prevention and treatment of polyoma virus infection and associated diseases.
Described herein is a UV/HEVL-filtering SiHy contact lens that not only has a relatively high UV/HEVL filtering capability but also has an aesthetic appealing color. The bulk silicone hydrogel of the UV/HEVL-filtering SiHy contact lens comprises repeating units of (1) at least one hydrophilic vinylic monomer, (2) at least one siloxane-containing vinylic monomer and/or at least one polysiloxane vinylic crosslinker, (3) at least one UV-absorbing vinylic monomer, and (4) a least one polymerizable HEVL-absorbing compound capable of absorbing HEVL between 380 nm and 450 nm and also comprises at least one blue-tinting agent and at least one optical brightener distributed therein.
39 - Transport, packaging, storage and travel services
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Business consulting services in the field of set-up,
practice and operation of radioligand imaging and
radioligand therapy; acceptance of online orders for ligands
and radioligands; administrative services in the field of
medical referrals. Delivery of ligands and radioligands. Educational services, namely, providing on-line classes,
seminars and workshops for healthcare professionals in the
field of radioligand imaging and radioligand therapy. Providing health information; Providing medical information
in the field of radioligand imaging and radioligand therapy.
The present disclosure generally relates to a trans-eustachian multi-function system. The trans-eustachian multi-function system comprises a body configured for disposition within a eustachian tube, the body comprising a proximal end, a distal end, a transverse cross-sectional shape, a longitudinally-extending length, an outer wall configured for disposition proximate a wall of the eustachian tube, and an inner portion defining a passageway; and a distal anchor disposed proximate the distal end, the distal anchor configured to releasably anchor the body against the wall of the eustachian tube.
Embodiments of the present disclosure generally relate to systems and methods for measuring intraocular pressure (IOP) during ophthalmic surgery. In some embodiments, a method for measuring IOP is provided. The method includes measuring fluid pressure in a fluid flow path of a handpiece device using a pressure sensor disposed therein to obtain a fluid pressure measurement, determining a sensor temperature measurement of the pressure sensor, determining a predicted sensor zero offset based on the sensor temperature measurement using a determined zero offset correlation function, and adjusting the fluid pressure measurement with the predicted sensor zero offset to obtain an adjusted fluid pressure measurement.
A61B 17/00 - Surgical instruments, devices or methods
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
12.
MODULAR INTRAOCULAR LENS DESIGNS, TOOLS AND METHODS
The Regents of the University of Colorado, a body corporate (USA)
Inventor
Kahook, Malik Y.
Sussman, Glenn
Zacher, Rudolph F.
Mclean, Paul J.
Uy, Harvey
Cionni, Robert
Solomon, Kerry
Abstract
Modular IOL systems including a base and a lens, wherein the lens includes tabs for connection to the base. The modular IOL allows for the lens to be adjusted or exchanged while leaving the base in place, either intra-operatively or post-operatively.
150mg/mL omalizumab formulation for use in a method of treatment of one or more of: allergic asthma; chronic rhinosinusitis with nasal polyps; chronic spontaneous urticaria; nasal polyps; food allergy; moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms inadequately controlled with inhaled corticosteroids, wherein the omalizumab is administered subcutaneously by a syringe.
The present disclosure generally relates to a trans-eustachian multi-function system. The trans-eustachian multi-function system comprises a body configured for disposition within a eustachian tube, the body comprising a proximal end, a distal end, a transverse cross-sectional shape, a longitudinally-extending length, an outer wall configured for disposition proximate a wall of the eustachian tube, and an inner portion defining a passageway; and a distal anchor disposed proximate the distal end, the distal anchor configured to releasably anchor the body against the wall of the eustachian tube.
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
A61B 1/015 - Control of fluid supply or evacuation
A61B 1/018 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor characterised by internal passages or accessories therefor for receiving instruments
A61B 1/227 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for ears, i.e. otoscopes
15.
SYSTEMS AND METHODS FOR DYNAMIC THERMAL COMPENSATION
Embodiments of the present disclosure generally relate to systems and methods for measuring intraocular pressure (IOP) during ophthalmic surgery. In some embodiments, a method for measuring IOP is provided. The method includes measuring fluid pressure in a fluid flow path of a handpiece device using a pressure sensor disposed therein to obtain a fluid pressure measurement, determining a sensor temperature measurement of the pressure sensor, determining a predicted sensor zero offset based on the sensor temperature measurement using a determined zero offset correlation function, and adjusting the fluid pressure measurement with the predicted sensor zero offset to obtain an adjusted fluid pressure measurement.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
G01L 27/00 - Testing or calibrating of apparatus for measuring fluid pressure
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
16.
MULTIDOSE PRESERVATIVE-FREE (MDPF) OPHTHALMIC DOSE DELIVERY WITH ADDITION OF FORMULATION SURFACTANTS
The present disclosure generally relates to ophthalmic compositions and multidose systems for topically applying compositions to a surface, e.g. an eye surface. Multidose systems of the present disclosure can include a multidose preservative-free (MDPF) eye dropper bottle system and an ophthalmic composition having an therapeutic agent, a viscosifying agent having a concentration of about 0.01 %w/v to about 5 %w/v, and a surfactant having a concentration of about 0.005 %w/v to about 7 %w/, wherein the composition lacks a preservative.
The present invention relates to siponimod (BAB312) for use in the treatment of an autoimmune disease, wherein an immediate release dosage form is administered once daily to a patient as maintenance regimen and wherein the patient has experienced a specific titration regimen with siponimod beforehand.
The present invention relates to the HDM2-p53 interaction inhibitor (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one (HDM201) for use in the treatment of hematological tumors, wherein the drug is administered following an extended low dose regimen characterized by a higher dose during induction and a lower dose during consolidation.
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
22.
STATE OF HEALTH EVALUATION OF ULTRASONIC HANDPIECE
A controller for an ultrasonic handpiece having a load in the form of at least one piezoelectric drive crystal includes a processor and a computer-readable storage memory on which is recorded a computer-readable instruction set. Execution of the instruction set during real-time operation of the handpiece causes the processor to perform an associated method, during which the processor calculates a load capacitance of the load and a dissipation factor of the load capacitance. The processor also records the load capacitance and dissipation factor in memory over time as a recorded capacitance history. The processor then executes a control action of the handpiece using the recorded capacitance history and possibly one or more additional recorded electrical parameters such as estimated resistance, estimated inductance, and/or measured temperature, or correlations of the same with resonant frequency over time.
G16H 40/60 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
A61B 17/00 - Surgical instruments, devices or methods
23.
ARTICULABLE OTOLOGIC SUCTION TUBE AND SUCTION TUBE SYSTEM
An otologic instrument includes a handle configured to be held by a hand of a surgeon and a cannula extending outwardly from the handle and mounted to the handle. An articulated tube is at least partially positioned within the cannula and at least partially extends outwardly from a distal end of the cannula. An actuator is configured to articulate the articulated tube relative to the cannula to position a distal end of the suction tube at a plurality of positions within a three-dimensional volume. The actuator may be configured to control extension of the articulated tube relative to the cannula, the articulated tube having a curved shape when undeformed. The actuator may be configured to pull a cable or push a push rod within the articulated tube to adjust the curvature of the articulated tube.
The present disclosure generally relates to ophthalmic compositions and multidose systems for topically applying compositions to a surface, e.g. an eye surface. Multidose systems of the present disclosure can include a multidose preservative-free (MDPF) eye dropper bottle system and an ophthalmic composition having an therapeutic agent, a viscosifying agent having a concentration of about 0.01% w/v to about 5% w/v, and a surfactant having a concentration of about 0.005% w/v to about 7% w/, wherein the composition lacks a preservative.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
A61K 31/4168 - 1,3-Diazoles having a nitrogen atom attached in position 2, e.g. clonidine
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A system and method for assisting a surgeon performing an ophthalmic procedure on an eye of a patient, the system including a lubrication assembly. The lubrication assembly may be disposed on a proximal end of a robotic arm, a proximal end of a surgical microscope, or a proximal end of a mobile stand or frame. Dispersal of lubricant from the lubrication assembly may be upon receipt of a direct input from a surgeon, according to a predetermined schedule, or according to an image processing protocol. The lubrication assembly may be moved into position over the eye of the patient manually by the surgeon or through the indirect command of a motion controller which is operable to move the robotic arm or the surgical microscope so as to extend the lubrication assembly into a desired position.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
A61B 34/20 - Surgical navigation systemsDevices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
Embodiments described herein relate generally to medical implant delivery apparatuses and methods. In some embodiments, an intracameral injector needle has a substantially cylindrical body defining a longitudinal flow path therein. The body has a proximal end, a distal end, an outer peripheral face and a bevel region, with the longitudinal flow path extending from the proximal end to the distal end. A first bevel of the bevel region has a first bevel angle with respect to the outer peripheral face. A second bevel of the bevel region extends from the first bevel to the proximal end. The second bevel includes a tip of the intracameral injector needle, and has a second bevel angle with respect to the outer peripheral face, where the second bevel angle is different from the first bevel angle, the first bevel and the second bevel defining a transition therebetween. The bevel region has a tapered width. The transition is at least one of: (1) longitudinally positioned between the tip of the intracameral injector needle and a location of a maximum width of the bevel region; and (2) vertically disposed at a position below 50% of a maximum height of the bevel region.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
An apparatus for delivering an implant to an eye using hydraulic fluid flow or pressure. An implant may be stored, advanced, and delivered to an eye using hydraulic fluid stored in a sterile container through a hollow advancement plunger. The plunger may rigidly advance the implant to a sealed position in a first phase, and then the implant may be advanced into the eye via hydraulic pressure or fluid flow in a second phase.
A controller for an ultrasonic handpiece having a load in the form of at least one piezoelectric drive crystal includes a processor and a computer-readable storage memory on which is recorded a computer-readable instruction set. Execution of the instruction set during real-time operation of the handpiece causes the processor to perform an associated method, during which the processor calculates a load capacitance of the load and a dissipation factor of the load capacitance. The processor also records the load capacitance and dissipation factor in memory over time as a recorded capacitance history. The processor then executes a control action of the handpiece using the recorded capacitance history and possibly one or more additional recorded electrical parameters such as estimated resistance, estimated inductance, and/or measured temperature, or correlations of the same with resonant frequency over time.
An otologic instrument includes a handle configured to be held by a hand of a surgeon and a cannula extending outwardly from the handle and mounted to the handle. An articulated tube is at least partially positioned within the cannula and at least partially extends outwardly from a distal end of the cannula. An actuator is configured to articulate the articulated tube relative to the cannula to position a distal end of the suction tube at a plurality of positions within a three-dimensional volume. The actuator may be configured to control extension of the articulated tube relative to the cannula, the articulated tube having a curved shape when undeformed. The actuator may be configured to pull a cable or push a push rod within the articulated tube to adjust the curvature of the articulated tube.
A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61B 17/29 - Forceps for use in minimally invasive surgery
A system and method for assisting a surgeon performing an ophthalmic procedure on an eye of a patient, the system including a lubrication assembly (170). The lubrication assembly may be disposed on a proximal end (172) of a robotic arm (167), a proximal end of a surgical microscope, or a proximal end of a mobile stand or frame. Dispersal of lubricant from the lubrication assembly may be upon receipt of a direct input from a surgeon, according to a predetermined schedule, or according to an image processing protocol. The lubrication assembly may be moved into position over the eye of the patient manually by the surgeon or through the indirect command of a motion controller which is operable to move the robotic arm or the surgical microscope so as to extend the lubrication assembly into a desired position.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
IL-18 participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
The present disclosure relates to methods of treating and/or preventing IgE driven allergic reaction to one or more allergens, preferably food allergens, in subjects having such disease or condition, comprising administering a therapeuticallly effective dose of LOU064.
10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1 ',2':4,5]pyrazino[1,2-B]pyridazine-3,5-dione Derivatives and Related Compounds as Inhibitors of the Orthomyxovirus Replication for Treating Influenza
The invention provides compounds of Formula (I):
The invention provides compounds of Formula (I):
The invention provides compounds of Formula (I):
as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.
The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Described herein are radiopharmaceuticals for the treatment of PSMA-expressing cancers, as well as methods and/or uses of such compounds for treating PSMA-expressing cancers, such as, e.g., metastatic castration resistant prostate cancers.
Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present disclosure relates to sulfonamide compounds, the use thereof for modulating the sodium channel Nav1.5 and methods of treating or preventing diseases, disorders, or conditions using the same.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
The present disclosure relates to methods for selectively reducing CysL97 in a preparation of IL-17 antibodies or antigen binding fragments thereof (e.g., a preparation of secukinumab antibodies) that have been recombinantly produced by mammalian cells. Also provided are purified preparations of IL-17 antibodies or antigen binding fragments thereof produced by such methods, e.g, purified preparations of secukinumab, wherein the level of intact IL-17 antibodies or antigen binding fragments thereof (e.g., secukinumab) in the preparation is high, e.g., at least about 90%, as measured by sodium dodecyl sulfate capillary electrophoresis (CE-SDS), and wherein the level of activity of IL-17 antibodies or antigen binding fragments thereof (e.g., secukinumab) in the preparation is high, e.g., at least about 92%, as measured by cation exchange chromatograph (CEX).
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
44.
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The present invention relates to novel pyridazin-3-yl phenol compounds of formula (I):
The present invention relates to novel pyridazin-3-yl phenol compounds of formula (I):
The present invention relates to novel pyridazin-3-yl phenol compounds of formula (I):
wherein R1, R2, R3, R4 and R5 are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
A method of treating a patient with of one or more of: allergic asthma; chronic rhinosinusitis with nasal polyps; chronic spontaneous urticaria; nasal polyps; food allergy; moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms inadequately controlled with inhaled corticosteroids, the method comprising administering 150 mg/mL omalizumab formulation, wherein the omalizumab is administered subcutaneously by a syringe.
A method of treating a patient with of one or more of: allergic asthma; chronic rhinosinusitis with nasal polyps; chronic spontaneous urticaria; nasal polyps; food allergy; moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms inadequately controlled with inhaled corticosteroids, the method comprising administering 150 mg/mL omalizumab formulation, wherein the omalizumab is administered subcutaneously by a syringe.
C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
39 - Transport, packaging, storage and travel services
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Business consulting services in the field involving the
implementation, practice and operation of radioligand
imaging and radioligand therapy; acceptance of online orders
for ligands and radioligands; administrative services in the
area of medical referrals. Delivery of ligands and radioligands. Educational services, namely, providing on-line classes,
seminars and workshops for healthcare professionals in the
field of radioligand imaging and radioligand therapy. Providing health information; Providing medical information
in the field of radioligand imaging and radioligand therapy.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
50.
3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof
The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Embodiments disclosed herein provide a surgical cassette including a housing having a base and a cover coupled to the base, wherein the cover and the base each at least partially define one or more channels. The housing further includes a plurality of ports formed in the base and in fluid communication with at least one of the one or more channels, a plurality of bores formed in the base and configured to receive one of a plurality of valve assemblies, and at least one pump landing formed in the base and configured to receive at least one pump assembly. A plurality of valve assemblies is disposed within the plurality of bores and configured to control fluid flow in the one or more channels of the housing. At least one pump assembly is disposed within the at least one pump landing and configured to provide a source of pressure or vacuum to the one or more channels of the housing.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
A61B 17/00 - Surgical instruments, devices or methods
An apparatus for implant into an eye. The apparatus may comprise a receptacle configured to receive an optic; a flange circumscribing the receptacle, the flange configured to be disposed in the ciliary sulcus of the eye; and a fenestration through the flange, the fenestration configured to allow aqueous humor to pass anteriorly from the ciliary body to the trabecular meshwork of the eye. Some or all of the apparatus may have an oleophobic coating. For example, some embodiments of the flange may have an oleophobic coating. In some embodiments, the fenestration may be inferior to the receptacle. Additionally, or alternatively, the apparatus may further comprise at least two haptics coupled to the flange.
In certain embodiments, an optical system for obtaining surgical information includes a probe housing a first optical fiber, a light source, a photoanalyzer, and an optical circulator optically coupled to each of the first optical fiber, the light source, and the photoanalyzer. The optical circulator has a first port configured to receive source light generated from the light source, a second port configured to transmit the source light from the first port to the first optical fiber, and a third port configured to transmit return light in the first optical fiber from the second port to the photoanalyzer. The first optical fiber is configured to emit at least a portion of the source light in the first optical fiber from the probe to contact a body structure, and collect light returning from the body structure as a result of the portion of the source light contacting the body structure.
A beam delivery system for a probe includes a plurality of laser sources configured to generate a respective incident beam, including a first laser source generating a first incident beam and a second laser source generating a second incident beam. The system includes routing structures respectively positioned along a path of the respective incident beam. An optical subsystem is adapted to sequentially direct a respective output beam from the routing structures into each core of a multi-core fiber in communication with the probe. The first routing structure and the second routing structure respectively include an array of optical elements adapted to be synchronously moved such that the first incident beam and the second incident beam encounter an identical member of the array at a same time.
Embodiments disclosed herein provide a surgical cassette including a housing having a base and a cover coupled to the base, wherein the cover and the base each at least partially define one or more channels. The housing further includes a plurality of ports formed in the base and in fluid communication with at least one of the one or more channels, a plurality of bores formed in the base and configured to receive one of a plurality of valve assemblies, and at least one pump landing formed in the base and configured to receive at least one pump assembly. A plurality of valve assemblies is disposed within the plurality of bores and configured to control fluid flow in the one or more channels of the housing. At least one pump assembly is disposed within the at least one pump landing and configured to provide a source of pressure or vacuum to the one or more channels of the housing.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
Described herein are methods of treating paroxysmal nocturnal hemoglobinuria (PNH) with the Factor B inhibitor LNP023 or a pharmaceutically acceptable salt thereof, e.g. LNP023 hydrochloride.
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 9/00 - Medicinal preparations characterised by special physical form
The present disclosure relates to methods for treating Chronic Spontaneous Urticaria using IgE antagonists, e.g., ligelizumab. Also disclosed herein are IgE antagonists, e.g., IgE antibodies, such as ligelizumab, for treating Chronic Spontaneous Urticaria patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.
A beam delivery system for a probe includes a plurality of laser sources configured to generate a respective incident beam, including a first laser source generating a first incident beam and a second laser source generating a second incident beam. The system includes routing structures respectively positioned along a path of the respective incident beam. An optical subsystem is adapted to sequentially direct a respective output beam from the routing structures into each core of a multi-core fiber in communication with the probe. The first routing structure and the second routing structure respectively include an array of optical elements adapted to be synchronously moved such that the first incident beam and the second incident beam encounter an identical member of the array at a same time.
Embodiments disclosed herein provide a surgical cassette that functions as an interface between a patient and a surgical console used to perform a variety of different ophthalmic surgeries.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
62.
SYSTEM AND METHOD FOR POST-OCCLUSION SURGE MITIGATION
According to certain embodiments, a surgical cassette for an ophthalmic surgical system comprises an irrigation conduit that is in fluid communication with a handpiece and carries fluid toward a surgical site. An aspiration conduit is in fluid communication with the handpiece and carries fluid away from the surgical site. An aspiration pump creates a vacuum pressure in the aspiration conduit to draw fluid through the aspiration conduit towards a drain reservoir. A reservoir couples with a pressure-vacuum source to manage the reservoir pressure. A valve is in fluid communication with the aspiration conduit and the reservoir, and provides one or more channels between the aspiration conduit and the reservoir. Each sensor detects a pressure associated with the surgical site. A computer controls the valve in response to the pressure detected by the one or more pressure sensors to mitigate a pressure or volume change.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
Embodiments disclosed herein provide a surgical cassette that functions as an interface between a patient and a surgical console used to perform a variety of different ophthalmic surgeries.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
An apparatus for implant into an eye. The apparatus may comprise a receptacle configured to receive an optic; a flange circumscribing the receptacle, the flange configured to be disposed in the ciliary sulcus of the eye; and a fenestration through the flange, the fenestration configured to allow aqueous humor to pass anteriorly from the ciliary body to the trabecular meshwork of the eye. Some or all of the apparatus may have an oleophobic coating. For example, some embodiments of the flange may have an oleophobic coating. In some embodiments, the fenestration may be inferior to the receptacle. Additionally, or alternatively, the apparatus may further comprise at least two haptics coupled to the flange.
According to certain embodiments, an ophthalmic system for providing an image of an eye includes a camera system and a computer. The camera system includes stereoscopic cameras that provide image data for images of the eye. The computer: receives the image data from the camera system; accesses overlay data for an overlay for the image of the eye; aligns the overlay data and the image data; digitally combines the overlay data and the image data to yield combined image data for an image with the overlay; and provides the combined image data to a display device to display the image with the overlay in three dimensions.
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
A61B 3/14 - Arrangements specially adapted for eye photography
G06T 7/30 - Determination of transform parameters for the alignment of images, i.e. image registration
H04N 13/239 - Image signal generators using stereoscopic image cameras using two 2D image sensors having a relative position equal to or related to the interocular distance
H04N 13/361 - Reproducing mixed stereoscopic imagesReproducing mixed monoscopic and stereoscopic images, e.g. a stereoscopic image overlay window on a monoscopic image background
68.
OCULAR IMPLANT WITH LEADING TIP AND METHOD OF DEPLOYMENT
Disclosed is an ocular implant with a flexible leading tip and methods of deploying the ocular implant. The leading tip can comprise a tip distal segment and a tip proximal segment. The leading tip can be tapered such that a diameter or width of the leading tip along the tip proximal segment is greater than the diameter or width of the leading tip along the tip distal segment.
The present disclosure relates to a fiber and a laser probe assembly with a probe tip that houses the fiber. In certain aspects, the fiber includes a core, an outer cladding surrounding the core, and an end face at a proximal and/or distal end of the fiber. The core is configured to transmit a laser light beam while the core and the outer cladding are both configured to transmit an illumination light. In certain aspects, a surface area of the end face corresponding to a cross-section of at least the outer cladding is treated with a roughening or polishing process to modulate an illumination light output angle of the fiber. Using a fiber that is configured to transmit a laser light beam as well as a wide-angle illumination light allows for a more compact fiber and probe tip, allowing for medical procedures that require a narrower probe.
Certain aspects of the present disclosure generally relate to ophthalmic surgery, and more particularly, to methods and apparatuses for controlling intraocular pressure (IOP) and administering ocular tamponades during or after ophthalmic surgery. An exemplary apparatus generally includes a proximal segment having a first inner diameter (ID), a first proximal end, and a first distal end. The apparatus further includes a distal segment having a second ID smaller than the first ID, a second proximal end, and a second distal end configured to be disposed inside a hub or a cannula transition of a valved cannula comprising the hub, a shaft, and the cannula transition between the hub and the shaft.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
The present disclosure relates to sulfonamide compounds, the use thereof for modulat-ing the sodium channel Nav1.5 and methods of treating or preventing diseases, disorders, or conditions using the same.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 249/02 - Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
C07D 233/00 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
C07D 231/02 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
The present disclosure relates to a method of treating prostate-specific membrane antigen (PSMA)-positive oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor comprising the administration of a therapeutically effective amount of a PSMA-binding radioligand therapeutic (RLT) agent, preferably [177Lu]Lu-PSMA-617 (lutetium (177Lu) vipivotide tetraxetan). Further, the present disclosure relates to radioligand therapy of early-stage prostate cancer patients to control recurrent tumor from progressing to fatal metastatic disease while preserving quality of life by delaying treatment with androgen deprivation therapy (ADT).
According to certain embodiments, an ophthalmic system for providing an image of an eye includes a camera system and a computer. The camera system includes stereoscopic cameras that provide image data for images of the eye. The computer: receives the image data from the camera system; accesses overlay data for an overlay for the image of the eye; aligns the overlay data and the image data; digitally combines the overlay data and the image data to yield combined image data for an image with the overlay; and provides the combined image data to a display device to display the image with the overlay in three dimensions.
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
A61B 3/14 - Arrangements specially adapted for eye photography
A novel combination comprising a 17 α-hydroxylase/C17,20 lyase inhibitor, for example: (3β)-17-(pyridin-3-yl)androsta-5,18-dien-3-ol or a pharmaceutically acceptable salt or ester thereof, and an AKT inhibitor, for example: N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, and optional additional antineoplastic agents; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of 17 α-hydroxylase/C17,20 lyase and/or AKT inhibition is beneficial, e.g., cancer.
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
In certain embodiments, a system for assessing a floater in the eye of a patient includes a display device, input device, and computer. The display device displays a target and background. The background has an alignment point and alignment axis. The eye axis of the eye is substantially aligned with the alignment axis when the eye is fixating on the alignment point. The input device receives patient input from the patient. The computer provides target display input to the display device to yield the target moving according to a pattern for the eye to follow. The eye axis moves relative to the alignment axis as the eye follows the moving target. The computer records patient input indicating that the patient sees the floater. The computer calculates a severity score, which indicates the severity of the floater, according to the patient input and generates a report that describes the severity score.
A61B 3/15 - Arrangements specially adapted for eye photography with means for aligning, spacing or blocking spurious reflection
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
In certain embodiments, a system for assessing a floater in the eye of a patient includes a display device, input device, and computer. The display device displays a target and background. The background has an alignment point and alignment axis. The eye axis of the eye is substantially aligned with the alignment axis when the eye is fixating on the alignment point. The input device receives patient input from the patient. The computer provides target display input to the display device to yield the target moving according to a pattern for the eye to follow. The eye axis moves relative to the alignment axis as the eye follows the moving target. The computer records patient input indicating that the patient sees the floater. The computer calculates a severity score, which indicates the severity of the floater, according to the patient input and generates a report that describes the severity score.
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
A61B 3/032 - Devices for presenting test symbols or characters, e.g. test chart projectors
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
A61B 3/15 - Arrangements specially adapted for eye photography with means for aligning, spacing or blocking spurious reflection
77.
OCULAR IMPLANT WITH LEADING TIP, LEADING TIP AND METHOD OF DEPLOYMENT
Disclosed is an ocular implant with a flexible leading tip and methods of deploying the ocular implant. The leading tip can comprise a tip distal segment and a tip proximal segment. The leading tip can be tapered such that a diameter or width of the leading tip along the tip proximal segment is greater than the diameter or width of the leading tip along the tip distal segment.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
providing an internet website portal offering the sale of products in the field of health and medical products, and the ability to administer and track these products, all for use by medical professionals and health treatment facilities; Providing business to business electronic commerce services for the purchase, administration and tracking of products in the fields of health and medicine
The present disclosure provides methods and kits for treating or preventing an allergic reaction to a food allergen consumed by a human subject with one or more food allergies. In particular, the present disclosure provides prophylactic therapies comprising administration of an anti-IgE antibody at a specific dose to a human subject who is allergic to one or more food allergens.
The Trustees of the University of Pennsylvania (USA)
Inventor
Beatty, Gregory
Engels, Boris
Idamakanti, Neeraja
June, Carl H.
Loew, Andreas
Song, Huijuan
Wu, Qilong
Abstract
Provided are compositions and methods for treating diseases associated with expression of mesothelin. Also provided are a chimeric antigen receptor (CAR) specific to mesothelin, vectors encoding the same, and recombinant T cells comprising the mesothelin CAR. Further provided are methods of administering a genetically modified T cell expressing a CAR that comprises a mesothelin binding domain.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
The present invention generally relates to crystalline polymorphic forms of the biaryl YAP/TAZ-TEAD protein-protein interaction inhibitors 4-((2S,4S)-5-Chloro-6-fluoro-2-phenyl-2-((S)-pyrrolidin-2-yl)-2,3-dihydrobenzofuran-4-yl)-5-fluoro-6-(2-hydroxyethoxy)-N-methylnicotinamide and 2-((2S,3S,4S)-5-Chloro-6-fluoro-3-methyl-2-((methylamino)methyl)-2-phenyl-2,3-dihydrobenzofuran-4-yl)-3-fluoro-4-methoxybenzamide and salts thereof, as well as methods of using the forms in the treatment of cancer.
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
C07D 307/81 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
The present invention describes engineered immunoglobulin IgG Fc regions by transferring structural elements, several CH2 inter-chain disulfide bonds, from IgA to IgG immunoglobulin. The disclosed Fc variants created thereof exhibit marked reductions or complete abrogation of interaction of the engineered Fc with FcγR and C1q while retaining natural ability to interact with FcRn at acidic pH. Silenced Fc molecules disclosed are in comparable expression and purification yields and improved or maintained thermostability compared to wild-type Fc, thereby limiting the propensity for aggregation. In addition, the disclosed Fc variant silencing mutations are capable of reducing or compensating destabilizing effects of other half-life extending or chain pairing facilitating Fc mutations.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
88.
METHODS FOR DETERMINING THE BIOLOGICAL ACTIVITY OF ANGPTL POLYPEPTIDES
Provided herein are methods for assaying the chondrogenesis-inducing activity of a therapeutic by measuring the expression and/or secretion levels of chondrogenesis biomarkers.
A method for assessing a lens capsule stability condition in an eye of a human patient includes directing electromagnetic energy in a predetermined spectrum onto a pupil of the eye, via an energy source, concurrently subsequent to a movement of the eye causing eye saccades to occur therein. The method also includes acquiring images of the eye indicative of the eye saccades using an image capture device, and computing, via the ECU, a motion curve of the lens capsule using the images. Additionally, the method includes extracting time-normalized lens capsule oscillation traces based on the motion curve via the ECU, and then model-fitting the lens capsule oscillation traces via the ECU to thereby assess the lens capsule instability condition. An automated system for performing an embodiment of the method is also disclosed herein, including the energy source, image capture device, and ECU.
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
The present invention relates to methods for treating small cell lung cancer (SCLC), in particular small cell lung cancer (SCLC) in a subject in need thereof wherein a therapeutically efficient amount of a radiopharmaceutical compound comprising a SSTR binding moiety, in particular [“Lu] Lu-DOTATE is administered to said subject in combination with one or more chemotherapeutic agents, such as carboplatin and etoposide, and, optionally an immune-oncology (I/O) agent, such as tislelizumab.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The invention provides compounds of Formula (1):
The invention provides compounds of Formula (1):
The invention provides compounds of Formula (1):
as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
The present disclosure provides methods and kits for treating or preventing an allergic reaction to a food allergen consumed by a human subject with one or more food allergies. In particular, the present disclosure provides prophylactic therapies comprising administration of an anti-IgE antibody at a specific dose to a human subject who is allergic to one or more food allergens.
A method for quantitively evaluating contact lens edge lift and distortion. The method includes the steps of scanning an edge of a contact lens, modeling the edge profile, determining a best-fit line over the modeled edge profile, calculating the slope of the best-fit line at a contact lens edge point, and further calculating a slope edge angle (ESA) as a function of the slope, wherein the ESA is a highly effective metric for capturing the contact lens edge-lift relative to the intended shape of the lens. The method may be used to provide design feedback, predict clinical fitting outcomes, and for quality control purposes.
Disclosed herein are systems and methods for compensating for a tilt of an intraocular lens (IOL) and systems and methods for adjusting the IOL. For example, one of the methods can comprise capturing one or more optical coherence tomography (OCT) images of an eye of a subject when the IOL is implanted within the eye of the subject. The method can also comprise generating a fixation target such that the fixation target is visible to the eye of the subject and moving the fixation target until a transverse plane of the IOL is perpendicular or substantially perpendicular to an optical axis of an ophthalmic system. The method can also comprise directing a laser beam generated by a laser of the ophthalmic system at the IOL.
Provided herein are azetidine pyrimidine compounds. In particular, provided herein are compounds that affect the function of kinases in a cell, and that are useful as therapeutic agents or with therapeutic agents. The compounds provided herein are useful in the treatment of a variety of diseases and conditions including inflammatory eye diseases such as uveitis, cardiovascular diseases, inflammatory diseases, and diseases characterized by abnormal growth, such as cancers. Also provided herein are compositions comprising azetidine pyrimidine compounds.
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A surgical knife for ear surgery includes a handle comprising a control mechanism and a shaft coupled to and extending distally from the distal end of the handle. A rod disposed within the shaft comprising a distal end and a proximal end opposite the distal end, wherein the proximal end of the rod is coupled to the control mechanism and wherein the rod is configured to translate along a longitudinal axis of the shaft upon actuation of the control mechanism. The surgical knife further includes a straight knife coupled to the distal end of the rod, wherein translation of the rod causes the straight knife to extend or retract out of the distal end of the shaft. The surgical knife further includes a round knife attached to the distal end of the shaft.
